drugset / Trial / NCT05760534

Ideal Dosage for Sedation of Obese Patients Undergoing Knee or Hip Arthroplasty Under Spinal Anesthesia

NCT05760534

Phase 4 Completed 110 enrolled Seoul National University Hospital
RandomizedParallel-groupDouble-blindTreatment

Summary

This study aims to compare ideal body weight- and total body weight-based dosage for remimazolam sedation of obese patients undergoing knee or hip arthroplasty under spinal anesthesia.

Timeline

Start
2023-03-06
Primary completion
2025-11-25
Completion
2025-11-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Remimazolam Small molecule 0.2 mg/kg
Subject Remimazolam Small molecule 1 mg/kg

Indications